(NASDAQ: VOR) Vor Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 62.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.25%.
Vor Biopharma's earnings in 2026 is -$2,449,551,000.On average, 8 Wall Street analysts forecast VOR's earnings for 2026 to be -$57,329,257, with the lowest VOR earnings forecast at -$113,858,978, and the highest VOR earnings forecast at -$15,194,314. On average, 7 Wall Street analysts forecast VOR's earnings for 2027 to be -$56,312,139, with the lowest VOR earnings forecast at -$82,027,436, and the highest VOR earnings forecast at -$12,898,771.
In 2028, VOR is forecast to generate -$61,616,355 in earnings, with the lowest earnings forecast at -$81,619,339 and the highest earnings forecast at -$40,663,921.